Management of inherited von Willebrand disease

Pier Mannuccio Mannucci, Augusto B. Federici

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

von Willebrand disease is a bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor. The diagnosis is based on measurements of plasma and platelet von Willebrand factor, the ability of von Willebrand factor to interact with its platelet receptor and the analysis of the multimeric composition of von Willebrand factor. Owing to the heterogeneity of von Willebrand factor defects, a correct diagnosis of types and subtypes may be sometimes difficult but is very important for an appropriate therapy. The aim of treatment is to correct the dual defects of haemostasis, i. e. abnormal coagulation, expressed by a low level of factor VIII, and abnormal platelet adhesion, expressed by a prolonged bleeding time. Desmopressin is the treatment of choice in patients with type I von Willebrand disease, who account for approximately 70% of cases, because it corrects the factor VIII/von Willebrand factor level and the prolonged bleeding time in most of these patients. In type 3 and in the majority of type 2 von Willebrand disease patients, desmopressin is not effective and it is necessary to resort to plasma concentrates containing factor VIII and von Willebrand factor. Treated with virucidal methods, these concentrates are effective and currently safe, but they do not always correct the bleeding time defect. Platelet concentrates or desmopressin can be used as adjunctive treatments when a poor correction of the bleeding time after concentrates is associated with continued bleeding. Studies are in progress, first to better characterize patients with type I von Willebrand disease and to determine their response to desmopressin, and second, to evaluate the pharmacokinetios of factor VIII following factor VIII/von Willebrand factor concentrates and to establish the indication for concentrates.

Original languageEnglish
Pages (from-to)455-462
Number of pages8
JournalBest Practice and Research: Clinical Haematology
Volume14
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

von Willebrand Diseases
von Willebrand Factor
Deamino Arginine Vasopressin
Bleeding Time
Platelets
Blood Platelets
Type 1 von Willebrand Disease
Defects
Factor VIII
Type 2 von Willebrand Disease
Hemorrhage
Plasmas
Therapeutics
Coagulation
Hemostasis
Adhesion
Chemical analysis
factor VIII, von Willebrand factor drug combination

Keywords

  • Congenital von Willebrand disease
  • Desmopressin
  • Factor VIII/von Willebrand factor concentrates
  • von Willebrand factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Management of inherited von Willebrand disease. / Mannucci, Pier Mannuccio; Federici, Augusto B.

In: Best Practice and Research: Clinical Haematology, Vol. 14, No. 2, 2001, p. 455-462.

Research output: Contribution to journalArticle

@article{6d6d2e3cf26d4ede9133eaecbf20caf6,
title = "Management of inherited von Willebrand disease",
abstract = "von Willebrand disease is a bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor. The diagnosis is based on measurements of plasma and platelet von Willebrand factor, the ability of von Willebrand factor to interact with its platelet receptor and the analysis of the multimeric composition of von Willebrand factor. Owing to the heterogeneity of von Willebrand factor defects, a correct diagnosis of types and subtypes may be sometimes difficult but is very important for an appropriate therapy. The aim of treatment is to correct the dual defects of haemostasis, i. e. abnormal coagulation, expressed by a low level of factor VIII, and abnormal platelet adhesion, expressed by a prolonged bleeding time. Desmopressin is the treatment of choice in patients with type I von Willebrand disease, who account for approximately 70{\%} of cases, because it corrects the factor VIII/von Willebrand factor level and the prolonged bleeding time in most of these patients. In type 3 and in the majority of type 2 von Willebrand disease patients, desmopressin is not effective and it is necessary to resort to plasma concentrates containing factor VIII and von Willebrand factor. Treated with virucidal methods, these concentrates are effective and currently safe, but they do not always correct the bleeding time defect. Platelet concentrates or desmopressin can be used as adjunctive treatments when a poor correction of the bleeding time after concentrates is associated with continued bleeding. Studies are in progress, first to better characterize patients with type I von Willebrand disease and to determine their response to desmopressin, and second, to evaluate the pharmacokinetios of factor VIII following factor VIII/von Willebrand factor concentrates and to establish the indication for concentrates.",
keywords = "Congenital von Willebrand disease, Desmopressin, Factor VIII/von Willebrand factor concentrates, von Willebrand factor",
author = "Mannucci, {Pier Mannuccio} and Federici, {Augusto B.}",
year = "2001",
doi = "10.1053/beha.2001.0143",
language = "English",
volume = "14",
pages = "455--462",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Management of inherited von Willebrand disease

AU - Mannucci, Pier Mannuccio

AU - Federici, Augusto B.

PY - 2001

Y1 - 2001

N2 - von Willebrand disease is a bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor. The diagnosis is based on measurements of plasma and platelet von Willebrand factor, the ability of von Willebrand factor to interact with its platelet receptor and the analysis of the multimeric composition of von Willebrand factor. Owing to the heterogeneity of von Willebrand factor defects, a correct diagnosis of types and subtypes may be sometimes difficult but is very important for an appropriate therapy. The aim of treatment is to correct the dual defects of haemostasis, i. e. abnormal coagulation, expressed by a low level of factor VIII, and abnormal platelet adhesion, expressed by a prolonged bleeding time. Desmopressin is the treatment of choice in patients with type I von Willebrand disease, who account for approximately 70% of cases, because it corrects the factor VIII/von Willebrand factor level and the prolonged bleeding time in most of these patients. In type 3 and in the majority of type 2 von Willebrand disease patients, desmopressin is not effective and it is necessary to resort to plasma concentrates containing factor VIII and von Willebrand factor. Treated with virucidal methods, these concentrates are effective and currently safe, but they do not always correct the bleeding time defect. Platelet concentrates or desmopressin can be used as adjunctive treatments when a poor correction of the bleeding time after concentrates is associated with continued bleeding. Studies are in progress, first to better characterize patients with type I von Willebrand disease and to determine their response to desmopressin, and second, to evaluate the pharmacokinetios of factor VIII following factor VIII/von Willebrand factor concentrates and to establish the indication for concentrates.

AB - von Willebrand disease is a bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor. The diagnosis is based on measurements of plasma and platelet von Willebrand factor, the ability of von Willebrand factor to interact with its platelet receptor and the analysis of the multimeric composition of von Willebrand factor. Owing to the heterogeneity of von Willebrand factor defects, a correct diagnosis of types and subtypes may be sometimes difficult but is very important for an appropriate therapy. The aim of treatment is to correct the dual defects of haemostasis, i. e. abnormal coagulation, expressed by a low level of factor VIII, and abnormal platelet adhesion, expressed by a prolonged bleeding time. Desmopressin is the treatment of choice in patients with type I von Willebrand disease, who account for approximately 70% of cases, because it corrects the factor VIII/von Willebrand factor level and the prolonged bleeding time in most of these patients. In type 3 and in the majority of type 2 von Willebrand disease patients, desmopressin is not effective and it is necessary to resort to plasma concentrates containing factor VIII and von Willebrand factor. Treated with virucidal methods, these concentrates are effective and currently safe, but they do not always correct the bleeding time defect. Platelet concentrates or desmopressin can be used as adjunctive treatments when a poor correction of the bleeding time after concentrates is associated with continued bleeding. Studies are in progress, first to better characterize patients with type I von Willebrand disease and to determine their response to desmopressin, and second, to evaluate the pharmacokinetios of factor VIII following factor VIII/von Willebrand factor concentrates and to establish the indication for concentrates.

KW - Congenital von Willebrand disease

KW - Desmopressin

KW - Factor VIII/von Willebrand factor concentrates

KW - von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=0034915927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034915927&partnerID=8YFLogxK

U2 - 10.1053/beha.2001.0143

DO - 10.1053/beha.2001.0143

M3 - Article

VL - 14

SP - 455

EP - 462

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 2

ER -